Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Castleman disease (CD) is a benign lymphoproliferative disorder that may present as a localized or multicentric form. The clinical manifestations are heterogeneous, ranging from asymptomatic discrete lymphadenopathy to recurrent episodes of diffuse lymphadenopathy with severe systemic symptoms.
Features include very common findings: Lymphadenopathy; and common findings: Weight loss, Low red blood cell count (anemia), Abdominal pain, and Follicular hyperplasia and others. 29 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 7 | Abdominal pain, Jaundice, Nausea and vomiting |
Biomarker and diagnostic research for Castleman disease has been reported in the published literature.
1 FDA-approved treatment is available for Castleman disease, including SILTUXIMAB (SYLVANT, approved 2014).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
Phenotype severity distribution: 1 very common feature, 10 common features.
Estimated prevalence: Unknown (Unknown prevalence).
17 clinical trials registered, 9 recruiting. Interventions under study include other interventions, drug therapy, and procedural interventions. Pipeline includes 5 PHASE2, 1 PHASE1, 1 NA. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03717844](https://clinicaltrials.gov/study/NCT03717844) |
Data assembled from 6 of 12 sources · Last updated Sep 18, 2026, 7:13 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Castleman disease
Blood and immune system
3 |
Low red blood cell count (anemia), Decreased mean corpuscular volume, Low platelet count (thrombocytopenia) |
Lab test results | 2 | Elevated CRP (inflammation marker) (elevated circulating c-reactive protein concentration), Increased circulating interleukin 6 concentration |
Kidneys and urinary system | 2 | Reduced kidney function (renal insufficiency), Blood in the urine (hematuria) |
Growth and development | 1 | Weight loss |
Brain and nerves | 1 | Fatigue |
Heart and blood vessels | 1 | Restrictive cardiomyopathy |
Lungs and breathing | 1 | Dyspnea |
SILTUXIMAB |
— |
2014 |
Available |
Gene therapy approaches for Castleman disease have been reported in the published literature.
17 trials found
Registry for Adults With Plasma Cell Disorders (PCD's) |
— |
UNC Lineberger Comprehensive Cancer Center |
RECRUITING |
[NCT07085039](https://clinicaltrials.gov/study/NCT07085039) | Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease | PHASE2 | University of Pennsylvania | RECRUITING |
[NCT02817997](https://clinicaltrials.gov/study/NCT02817997) | International Registry for Patients With Castleman Disease | — | University of Pennsylvania | RECRUITING |
[NCT06052618](https://clinicaltrials.gov/study/NCT06052618) | Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS) | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
[NCT00006518](https://clinicaltrials.gov/study/NCT00006518) | Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer | — | National Cancer Institute (NCI) | RECRUITING |
315 publications have been identified in PubMed for Castleman disease. Kisho has analyzed 185 by research type. Research spans Case Report / Case Series (41%), Review / Meta-Analysis (33%), and Epidemiology / Natural History (8%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 75 | 41% |
Research summaries | 61 | 33% |
Disease patterns and progression | 15 | 8% |
Laboratory research | 11 | 6% |
Clinical study results | 8 | 4% |
Other research | 7 | 4% |
Testing and diagnosis research | 7 | 4% |
New treatment approaches | 1 | 1% |
Kamarádová K (2026). [PMID: 41996258](https://pubmed.ncbi.nlm.nih.gov/41996258/). *Cesk Patol*. [Review / Meta-Analysis]
Li XR (2026). [PMID: 42103654](https://pubmed.ncbi.nlm.nih.gov/42103654/). *Zhonghua Nei Ke Za Zhi*. [Case Report / Case Series]
Alapat DV (2026). [PMID: 41774910](https://pubmed.ncbi.nlm.nih.gov/41774910/). *Am J Clin Pathol*. [Review / Meta-Analysis]
Chen LYC (2026). [PMID: 40457814](https://pubmed.ncbi.nlm.nih.gov/40457814/). *Arthritis & rheumatology (Hoboken, N.J.)*. [Review / Meta-Analysis]
Zhang L (2026). [PMID: 41952675](https://pubmed.ncbi.nlm.nih.gov/41952675/). *Front Oncol*. [Case Report / Case Series]
Ono S (2026). [PMID: 41065673](https://pubmed.ncbi.nlm.nih.gov/41065673/). *Mod Rheumatol*. [Case Report / Case Series]
Laczko D (2026). [PMID: 41802815](https://pubmed.ncbi.nlm.nih.gov/41802815/). *American journal of clinical pathology*. [Review / Meta-Analysis]
Zhang W (2026). [PMID: 42022320](https://pubmed.ncbi.nlm.nih.gov/42022320/). *Front Oncol*. [Case Report / Case Series]
Sastre Ortega J (2026). [PMID: 42014163](https://pubmed.ncbi.nlm.nih.gov/42014163/). *BMJ Case Rep*. [Case Report / Case Series]
Rogges E (2026). [PMID: 41996261](https://pubmed.ncbi.nlm.nih.gov/41996261/). *Cesk Patol*. [Review / Meta-Analysis]
AI-curated news mentioning Castleman disease
Updated Sep 16, 2026
A recent study published in PubMed examines the clinical characteristics and surgical outcomes of retroperitoneal unicentric Castleman disease. This single-center retrospective analysis provides valuable insights into patient management and treatment efficacy.
Recent research highlights new management strategies for Castleman disease, aiming to improve patient outcomes. These findings could influence future treatment protocols and clinical practices.
A Canadian center has applied modern classification methods to improve the understanding of Castleman disease. This research aims to enhance diagnostic accuracy and treatment approaches for this rare condition.